The ambiguity is further complicated because of the complex interplay between diabetes, pancreatitis and pancreatic cancer.
Patients with T2DM are at twofold to threefold increased risk of developing pancreatitis compared to patients without T2DM. 9 Additionally, long-standing T2DM doubles the risk of pancreatic cancer, while presentation of new-onset diabetes in patients with pancreatic cancer is not uncommon. 10 In the context of a noninterventional postauthorization vildagliptin safety study-undertaken as part of a commitment to the European Committee for Medicinal Products for Human Use (CHMP), 11 we conducted an exploratory analysis to assess the risk of acute pancreatitis and pancreatic cancer in patients with T2DM
using vildagliptin or vildagliptin/metformin (as a fixed-dose combination) compared with other noninsulin antidiabetic drugs (NIADs).
| MATERIAL S AND ME THODS

| Study design and databases
For this population-based, analytical, multidatabase cohort study, 11 we used information from The Clinical Practice Research
Datalink General practice OnLine Database (CPRD GOLD, UK),
Intercontinental Marketing Statistics Disease Analyzer (IMS DA)
Germany, IMS DA France, the Odense Pharmacoepidemiological Database (OPED) Denmark and the Swedish National Registers (NR).
| Patients and assessments
Patients with T2DM aged ≥18 years who were prescribed an NIAD 
| Statistical analysis
| Ethics and good clinical practice
| RE SULTS
Of totally 738 054 included NIAD users, 20 973 (2.8%) received vildagliptin at any time during the study. The mean duration of follow-up for vildagliptin users was 1.4 years corresponding to 28 330
PYs of exposure. Overall, the baseline characteristics of patients were comparable between vildagliptin and other NIADs across databases ( Table 1 ).
The age-/sex-adjusted IRRs for acute pancreatitis (vildagliptin vs. (Figure 3 ).
| D ISCUSS I ON
The findings from the present multidatabase study revealed that A meta-analysis of RCTs 6 and various large noninterventional studies [16] [17] [18] did not show an increased risk of pancreatic cancer in association with DPP-4 inhibitors.
In conclusion, this study suggests that the use of vildagliptin under real-world conditions is not associated with increased risk of pancreatitis compared with other NIADs. The increased risk of pancreatic cancer observed in some of the per protocol analyses are to be interpreted carefully as this study was originally not designed to assess pancreatic cancer and rather be explained by certain underlying limitations including latency time, chance findings and/or bias and other confounding factors (eg, smoking or alcoholism).
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